Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR solid tumors Second program targeting KIF18A anticipated to enter the clinic in 1H 2025, treating patients with chromosomally instable…